Kim Honsoul, Kim Myeong-Jin, Park Mi-Suk, Cha Seung-Whan, Lim Joon Seok, Yoo Hyung Sik, Kim Ki Whang
Department of Radiology, Yonsei University Health System, Seoul, Republic of Korea.
J Comput Assist Tomogr. 2010 Jan;34(1):113-20. doi: 10.1097/RCT.0b013e3181aacd6b.
To identify conditions that might impair the delayed selective hepatobiliary enhancement of gadobenate dimeglumine.
Ninety-five gadobenate-enhanced magnetic resonance imaging studies were retrospectively and independently analyzed. The effects of selective hepatic enhancement and biliary excretion were each categorized into 3 grades according to the perceived difference of signal intensity between the liver parenchyma and portal vein, and signal intensity in the common bile duct of precontrast- and delayed-phase images.History of diffuse liver disease, liver cirrhosis, and renal disease; elevated levels of blood urea nitrogen (BUN)/creatinine (Cr), aspartate aminotransferase (AST)/alanine aminotransferase, bilirubin, and alkaline phosphatase (ALP); ascites; and splenomegaly were compared according to the grade of hepatic and biliary enhancement.
Diffuse liver disease (P = 0.002); cirrhosis (P < 0.001); renal disease (P = 0.022); ascites (P = 0.001); splenomegaly (P < 0.001); and elevated levels of BUN (P = 0.001), Cr (P = 0.003), AST (P < 0.001), bilirubin (P < 0.001), and ALP (P < 0.001) were factors that impaired selective hepatic enhancement. Biliary excretion was affected by the presence of liver disease (P < 0.001), cirrhosis (P < 0.001), splenomegaly (P < 0.001), ascites (P = 0.002), and elevated levels of Cr (P = 0.013), AST (<0.001), alanine aminotransferase (P = 0.001), bilirubin (P < 0.001), and ALP (P < 0.001).
Delayed selective hepatobiliary enhancement of gadobenate dimeglumine can be impaired by liver or renal disease and/or by elevated levels of bilirubin, ALP, BUN, and Cr.
确定可能损害钆贝葡胺延迟选择性肝胆强化的情况。
对95项钆贝葡胺增强磁共振成像研究进行回顾性独立分析。根据肝实质与门静脉之间信号强度的感知差异以及造影前和延迟期图像中胆总管的信号强度，将选择性肝脏强化和胆汁排泄的效果分别分为3级。比较弥漫性肝病、肝硬化和肾病病史；血尿素氮（BUN）/肌酐（Cr）、天冬氨酸转氨酶（AST）/丙氨酸转氨酶、胆红素和碱性磷酸酶（ALP）水平升高；腹水；以及脾肿大与肝脏和胆汁强化分级的关系。
弥漫性肝病（P = 0.002）；肝硬化（P < 0.001）；肾病（P = 0.022）；腹水（P = 0.001）；脾肿大（P < 0.001）；以及BUN（P = 0.001）、Cr（P = 0.003）、AST（P < 0.001）、胆红素（P < 0.001）和ALP（P < 0.001）水平升高是损害选择性肝脏强化的因素。胆汁排泄受肝病（P < 0.001）、肝硬化（P < 0.001）、脾肿大（P < 0.001）、腹水（P = 0.002）以及Cr（P = 0.013）、AST（<0.001）、丙氨酸转氨酶（P = 0.001）、胆红素（P < 0.001）和ALP（P < 0.001）水平升高的影响。
钆贝葡胺的延迟选择性肝胆强化可能会受到肝脏或肾脏疾病和/或胆红素、ALP、BUN及Cr水平升高的损害。
